Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.
BACKGROUND
HER-2 overexpression is an independent predictor for poor prognosis of breast cancer patients. Recently, extracellular domain of HER-2 (ECD) was found detectable in the serum of breast cancer patients. In this prospective study, we wonder whether ECD levels predict the clinical outcome of metastatic breast cancer patients.


METHODS
ECD were measured in 190 women with metastatic breast cancer. Chi-square test was performed to determine the relationship between ECD status and clinical outcomes. Kaplan-Meier curves were applied for survival analysis.


RESULTS
Elevated ECD levels were significantly associated with short-term response to Herceptin treatment. The median PFS was significantly longer in ECD-Low patients. The patients who remained low ECD levels or achieved low ECD levels after treatments have significantly longer PFS than those whose levels remained high or converted from low to high.


CONCLUSIONS
Overall, our results support the clinical utility of measuring serum HER2 ECD levels in patients with advanced breast cancer. Baseline and serial measurements of serum ECD levels are reliably predictive of clinical outcome of breast cancer patients.
Department of Medical Oncology, Zhejiang Cancer Hospital Hangzhou, China.
Xiying
X
Shao
Department of Medical Oncology, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University Hangzhou, China.
Xian
X
Wang
Zhejiang Cancer Institute, Zhejiang Province Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology Hangzhou, China.
Xiaohong
X
Xu
Zhejiang Cancer Institute, Zhejiang Province Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology Hangzhou, China.
Jianguo
J
Feng
Hangzhou Polar Gene Co., LTD Hangzhou, China.
Mark
M
Han
Hangzhou Polar Gene Co., LTD Hangzhou, China.
Han
H
Zhang
Department of Medical Oncology, Zhejiang Cancer Hospital Hangzhou, China.
Zhan-Hong
ZH
Chen
Zhejiang Cancer Institute, Zhejiang Province Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology Hangzhou, China.
Sheng
S
Wang
Zhejiang Cancer Institute, Zhejiang Province Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology Hangzhou, China.
Yi-Min
YM
Zang
Department of Medical Oncology, Zhejiang Cancer Hospital Hangzhou, China.
Ping
P
Huang
Department of Medical Oncology, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University Hangzhou, China.
Hongchuan
H
Jin
Department of Medical Oncology, Zhejiang Cancer Hospital Hangzhou, China ; Department of Medical Oncology, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University Hangzhou, China.
Xiaojia
X
Wang
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D011379:Prognosis; D017434:Protein Structure, Tertiary; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
Epidermal growth factor receptor-2 (EGFR-2); extracellular domain; metastatic breast cancer